  - Health M&A could increase in 2013, analysts say
Health companies have large cash reserves, and drugmakers are shifting their focus from cost-cutting to filling pipelines through mergers and acquisitions, industry analysts say. Next year could top the 2,076 health deals worth $166 billion announced in the past 12 months. "What tends to drive that is the need. There's clearly a need for larger companies who are facing patent cliffs and whose own R&D machines have not panned out, to find growth," he said. Bloomberg (10/25)       | New Technologies Give Older Drugs a Makeover | | The disappointing returns on biopharmaceutical research and development, despite the availability of advanced molecular technologies and the investment of billions of dollars, is forcing companies to re-evaluate their business plans. One idea that is coming back into vogue again is the strategy of giving older drugs a makeover. Find out the details. |  |
| Health Care & Policy |  |  | | - OncoMed contracts Lonza to manufacture cancer drugs
Lonza will develop and manufacture OncoMed's pipeline of experimental stem cell treatments for cancer. The deal covers OncoMed's demcizumab, anti-Notch, anti-Notch 2/3, anti-Fzd7, anti-DLL4/VEGF treatments and other monoclonal antibodies. "This multi-product contract and GS license agreement demonstrate Lonza's ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product life cycle," said Stephan Kutzer, chief operating officer custom manufacturing at Lonza. Pharmaceutical Business Review Online (10/26) | Company & Financial News | | | | | Food & Agriculture | | | | | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - BP ends plans for Fla. cellulosic-ethanol project
BP is dropping its proposed $300 million cellulosic-ethanol plant project in Highlands County, Fla., the company said. BP will focus its U.S. biofuels efforts on technology licensing and research and development. "In order to make the large capital investments necessary to commercialize advanced and cellulosic biofuels, companies need to know that the U.S. is committed to achieving energy security and that the Renewable Fuel Standard is here to stay," said BIO Executive Vice President Brent Erickson. BiofuelsDigest.com (10/26), Bloomberg Businessweek (10/25) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | Being inexhaustible, life and nature are a constant stimulus for a creative mind."
--Hans Hoffman,
German-American abstract expressionist painter  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, October 26, 2012
- Thursday, October 25, 2012
- Wednesday, October 24, 2012
- Tuesday, October 23, 2012
- Monday, October 22, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment